1PX

PHOENIX NEW MED.ADR 1/48

Communication Services · EUR · F

1PX

Price

€1.329

-6.08%

Cap

€20.42M

Earnings

30d Trend

-8.7%

1PX
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityModerate

30% annualised over 90 days

BRAIN47 SIGNAL

0
WEAK
Risk Level62
Quality20
Momentum29
Technical37
Fundamentals35

Raw weighted: 34×Macro 0.99 (1%)=34

RISK

62/100
90d Volatility
30.0%Moderate
ATR %
3.0%Normal
Max Drawdown (1Y)
-46.6%Volatile

QUALITY

20/100
ROE (avg)
4.6%Weak

MOMENTUM

29/100
12-1M Momentum
-18.8%Strong downtrend
6-1M Momentum
-18.4%Negative
1M Return
-2.3%Stable
Relative Strength
-2.2% vs sectorIn-line

TECHNICAL

37/100
RSI (14)
42.8Neutral
Price vs SMA200
-18.0%Bearish trend
MACD
0.00Bearish momentum
Bollinger Band
23%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.083Noisy/choppy

FUNDAMENTALS

35/100
P/S
6.0Fair

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months41
3-12 months31
1-5+ years28

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate PHOENIX NEW MED.ADR 1/48 at 34/100 — a WEAK reading on the Brain47 Signal. The strongest factor is risk management at 38/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-2.3%

3 MONTHS

-3.4%

12 MONTHS

-21.1%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. low-risk profile and Technical (37) are the primary strengths. I note that quality is the weakest area at 20/100 — this warrants monitoring. Historical volatility is moderate at 30%. I classify this as a speculative position — risk characteristics and smaller market cap define the opportunity.

speculativeScore: 34/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.